Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
MLYSthis companyMineralys Therapeutics, Inc.	$15.87	-15.85×	3.8×	0×	-14.76×	-83.7%	0.0%	0.0%	0.0%	-23.9%	-26.4%	-5.8%	0×	1.12×	0×	43.76×	0.0%	2	4.94	2	C
DMACDiaMedica Therapeutics Inc.	$9.76	-11.37×	6.66×	0×	-10.97×	-96.7%	0.0%	0.0%	0.0%	-58.4%	-61.0%	-7.8%	0×	0.47×	0×	11.81×	0.0%	1	37.36	2	C
MAZEMaze Therapeutics, Inc.	$34.30	-13.58×	5.02×	0×	-12.54×	-87.4%	0.0%	0.0%	0.0%	-36.9%	-37.7%	-6.3%	0.07×	1.29×	0×	15.5×	0.0%	3	11.54	2	C
OBIOOrchestra BioMed Holdings, Inc.	$5.68	-3.74×	3.13×	5.92×	-3.5×	-202.6%	99.4%	-154.7%	-157.4%	-83.2%	-52.4%	-25.0%	0.25×	0.37×	-45.13×	6.45×	0.0%	3	-2.89	1	D+
TVTXTravere Therapeutics, Inc.	$50.45	-68.23×	29.69×	6.95×	164.03×	-591.5%	97.9%	-12.8%	-5.2%	-22.2%	-13.9%	-0.6%	2.86×	10.61×	-5.85×	2.74×	0.0%	4	1.52	1	D+
UNCYUnicycive Therapeutics, Inc.	$3.71	-3.46×	3.04×	0×	-2.42×	-48.2%	0.0%	0.0%	0.0%	-87.9%	-97.1%	-34.2%	0.01×	1.12×	-415.73×	2.59×	0.0%	2	-0.44	2	C+
Peer median	—	-11.37×	5.02×	0×	-3.5×	-96.7%	0.0%	0.0%	0.0%	-58.4%	-52.4%	-7.8%	0.07×	1.12×	-5.85×	6.45×	0.0%	3	1.52	2	—